Vicente E. Torres
Consultant, Division of Nephrology & Hypertension, Department of Internal Medicine · Mayo Clinic
Credentials: · · ·
History
- Present
Hospital Clinico y Provincial de Barcelona Faculty of Medicine
Hospital Clinico y Provincial de Barcelona Faculty of Medicine
Universidad de Barcelona
Research
New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race
New England Journal of Medicine · 2021 · 3,857 citations
Tolvaptan in patients with autosomal dominant polycystic kidney disease
New England Journal of Medicine · 2012 · First of 11 authors · Corresponding · 1,273 citations
Autosomal dominant polycystic kidney disease
Review · The Lancet · 2007 · First of 3 authors · Corresponding · 1,087 citations
98 papers
63 papers
- KB
56 papers
54 papers · 1 as a fellow
- BK
44 papers
- JG
44 papers
42 papers
- TS
29 papers
Grants
- 2010–2020
Mayo Translational PKD Center (MTPC)
National Institute of Diabetes and Digestive and Kidney Diseases · P30
Contact PI · $11.8M · Mayo Clinic Rochester
- 1991–2020
Novel Treatment for Polycystic Kidney Disease
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $5.8M · Mayo Clinic Rochester
- 2017–2018
FASEB SRC on Polycystic Kidney Disease: Challenges, Differing Viewpoints and Ways Forward
National Institute of Diabetes and Digestive and Kidney Diseases · R13
Contact PI · $10K · Federation of Amer Soc for Exper Biology
- 1995–2016
Novel Treatment for Polycystic Kidney Disease
National Institute of Diabetes and Digestive and Kidney Diseases · R56
Contact PI · $119.3K · Mayo Clinic Rochester
Clinical trials
- 2021–2022
Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
Principal investigator · Terminated · Phase 3
Palladio Biosciences
- 2018–2020
Principal investigator · Completed · Phase 2
Palladio Biosciences
- 2007–2012
Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Principal investigator · Completed · Phase 3
Otsuka Pharmaceutical Development & Commercialization, Inc.
- 2006–2014
HALT Progression of Polycystic Kidney Disease Study A
Principal investigator · Completed · Phase 3
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)